NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









VALANX Biotech

VALANX Biotech

Private
ViennaHealthcare & Life Scienceshttps://www.valanx.bio/

Last Round

Series A

Mar 12, 2026

Total Funding Raised

$3.55M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

VALANX Biotech is a biotechnology company that has developed a proprietary platform for site-specific protein conjugation to create antibody-drug conjugates (ADCs) and other biologics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

antibody-drug conjugatesADCsite-specific protein conjugationbioconjugationbiotech platformclick chemistryprotein engineeringcancer therapydrug discoverybiotherapeuticsplatform licensingsynthetic biologyvaccine developmentcarrier protein

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

VALANX Biotech Comps

Public and private peers based on sector, stage, and business model.

VALANX Biotech comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

VALANX Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 12, 2026
VC RoundNov 7, 2023
SeedMay 1, 2020
AcceleratorJun 16, 2017

VALANX Biotech Investors

Notable investors and investment history

VALANX Biotech investors
InvestorRounds
tecnet equitySeed, Series A, VC Round
SkygeneSeries A, VC Round
xista science venturesSeed, VC Round
xista science venturesSeries A
RebelBioAccelerator
SOSVSeed, Series A, VC Round, Accelerator
Fondation Fournier-MajoieSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 2, 2026

    Grew 21% QoQ, from 14 to 17 employees.

  • Apr 15, 2026

    Monthly visitors increased 144% MoM, reaching 268.

VALANX Biotech Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

VALANX Biotech Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about VALANX Biotech's valuation, stock price, and market status.

Firmographic Details

HeadquartersVienna
Employee Range17
Year Founded2017
Last FundingMar 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.